BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9398471)

  • 1. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
    Bezard E; Dovero S; Bioulac B; Gross C
    Exp Neurol; 1997 Nov; 148(1):288-92. PubMed ID: 9398471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
    J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
    Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
    Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
    Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
    J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
    Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP.
    Walters TL; Irwin I; Delfani K; Langston JW; Janson AM
    Exp Neurol; 1999 Mar; 156(1):62-70. PubMed ID: 10192777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W; Sripanichkulchai K; Finkelstein DI
    Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.
    Kurkowska-Jastrzebska I; Litwin T; Joniec I; Ciesielska A; Przybyłkowski A; Członkowski A; Członkowska A
    Int Immunopharmacol; 2004 Oct; 4(10-11):1307-18. PubMed ID: 15313429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
    Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
    Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
    Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
    Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
    Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels.
    Cao XQ; Arai H; Ren YR; Oizumi H; Zhang N; Seike S; Furuya T; Yasuda T; Mizuno Y; Mochizuki H
    J Neurochem; 2006 Nov; 99(3):861-7. PubMed ID: 17076657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.